Drugs / TAK-816
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02074345 | Mar 2014 → Mar 2015 | haemophilus meningitis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01379846 | Jun 2011 → Feb 2013 | — | Takeda | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-816 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02074345 ↗ |
| Modality | Vaccine | “TAK-816 is a conjugated Hib vaccine” NCT01379846 ↗ |
| Route | Intramuscular | “TAK-816 intramuscular injection” NCT02074345 ↗ |